Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FRD NYSEMKT:IGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRDFriedman Industries$21.05-4.0%$17.95$12.24▼$22.96$148.59M1.4824,702 shs12,528 shsIGCIGC Pharma$0.42+27.3%$0.38$0.25▼$0.48$39.05M1.08913,992 shs214,616 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRDFriedman Industries+2.81%+2.53%+27.96%+31.18%+2,191,999,900.00%IGCIGC Pharma+0.49%+1.22%+11.29%+35.74%+21.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRDFriedman Industries$21.05-4.0%$17.95$12.24▼$22.96$148.59M1.4824,702 shs12,528 shsIGCIGC Pharma$0.42+27.3%$0.38$0.25▼$0.48$39.05M1.08913,992 shs214,616 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRDFriedman Industries+2.81%+2.53%+27.96%+31.18%+2,191,999,900.00%IGCIGC Pharma+0.49%+1.22%+11.29%+35.74%+21.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFRDFriedman Industries 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.88833.73% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFRDFriedman Industries$464.83M0.32$1.33 per share15.84$19.00 per share1.11IGCIGC Pharma$1.33M28.40N/AN/A$0.08 per share5.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFRDFriedman Industries$6.09M$1.2017.54∞N/A1.84%6.50%3.95%N/AIGCIGC Pharma-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/ALatest IGC, SML, KFE, and FRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q1 2026FRDFriedman IndustriesN/A$0.71N/A$0.71N/A$134.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFRDFriedman Industries$0.160.76%N/A13.33%1 YearsIGCIGC PharmaN/AN/AN/AN/AN/ALatest IGC, SML, KFE, and FRD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/18/2025FRDFriedman Industriesquarterly$0.040.73%10/24/202511/14/20259/18/2025FRDFriedman Industriesquarterly$0.040.73%10/24/202511/14/20256/25/2025FRDFriedman Industriesquarterly$0.041%7/18/20257/18/20258/8/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFRDFriedman IndustriesN/A3.901.35IGCIGC Pharma0.021.150.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFRDFriedman Industries33.26%IGCIGC Pharma3.87%Insider OwnershipCompanyInsider OwnershipFRDFriedman Industries5.50%IGCIGC Pharma23.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFRDFriedman Industries1007.06 million6.67 millionN/AIGCIGC Pharma6190.81 million54.60 millionN/AIGC, SML, KFE, and FRD HeadlinesRecent News About These CompaniesIGC Pharma (NYSEMKT:IGC) Shares Up 28.5% - Still a Buy?September 10, 2025 | americanbankingnews.comIGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's DetectionSeptember 9, 2025 | accessnewswire.comAIGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in CanadaSeptember 2, 2025 | accessnewswire.comAIGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's SyndromeAugust 28, 2025 | accessnewswire.comAIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong ...August 28, 2025 | finance.yahoo.comIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.August 27, 2025 | accessnewswire.comAIGC Pharma expands CALMA Phase 2 trial with Lynn Health Science Institute siteAugust 25, 2025 | msn.comIGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma CityAugust 25, 2025 | accessnewswire.comAIGC Pharma, Inc.: IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's TrialAugust 19, 2025 | finanznachrichten.deIGC Pharma reports Q1 EPS (2c) vs. (3c) last yearAugust 19, 2025 | msn.comIGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's TrialAugust 19, 2025 | accessnewswire.comAIGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue EstimatesAugust 14, 2025 | zacks.comIGC Pharma, Inc.: IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1August 13, 2025 | finanznachrichten.deIGC Pharma highlights preclinical data on IGC-M3August 12, 2025 | msn.comIGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1August 12, 2025 | accessnewswire.comAIGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease ProgressionAugust 5, 2025 | accessnewswire.comAIGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025July 23, 2025 | accessnewswire.comAIGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience AwardsJuly 21, 2025 | accessnewswire.comAIGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict ...July 12, 2025 | morningstar.comMIGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early DetectionJuly 11, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025ASML Has Entered Buy Territory, But Only For Patient InvestorsBy Gabriel Osorio-Mazilli | August 21, 2025IGC, SML, KFE, and FRD Company DescriptionsFriedman Industries NASDAQ:FRD$21.05 -0.87 (-3.97%) As of 10:33 AM EasternFriedman Industries, Incorporated engages in steel processing, pipe manufacturing and processing, and the steel and pipe distribution businesses the United States. It operates in two segments, Coil and Tubular. The Coil segment is involved in the conversion of steel coils into flat sheet and plate steel cut to customer specifications and reselling steel coils. This segment also processes customer-owned coils on a fee basis. The company sells coil products and processing services to approximately 200 customers located primarily in the midwestern, southwestern and southeastern regions of the United States. Its principal customers for these products and services are steel distributors and customers manufacturing steel products, such as steel buildings, railroad cars, barges, tanks and containers, trailers, component parts and other fabricated steel products. The Tubular segment manufactures line and oil country pipes, as well as pipes for structural applications. This segment sells its tubular products principally to steel and pipe distributors through its own sales force. The company was incorporated in 1965 and is headquartered in Longview, Texas.IGC Pharma NYSEMKT:IGC$0.42 +0.09 (+27.26%) As of 11:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
